| |
Subscription-based business models are vital for successful direct-to-consumer (DTC) testing. Discover the ins and outs of DTC testing and how to outlast the competition in this free guide. Download Now.
|
|
Today's Big NewsJan 12, 2023 |
|
March 14-15, 2023 | San Francisco, CA Gain valuable insight from cross-functional team members responsible for search and evaluation, legal/IP, portfolio management, strategic alliances, business development and licensing. Register today to secure our lowest rates!
|
|
| By Gabrielle Masson Novartis' Chief Medical Officer Shreeram Aradhye, M.D., is back after a muscle-building stint in biotech, jumping into 2023 laser-focused on five therapeutic areas and driven by the company’s goal of becoming a top U.S. drugmaker. |
|
|
|
By Nick Paul Taylor Sanofi has thrown its financial weight behind its venture capital unit, making a $750 million, multi-year commitment to enable the financier to build on a year in which it backed 10 companies globally. |
By Nick Paul Taylor Oramed Pharmaceuticals’ dream of developing an oral insulin for type 2 diabetes looks to be over. With the candidate failing to beat placebo in a phase 3 trial, the biotech outlined plans to stop development and sent its share price tumbling in the process. |
Sponsored by Personalis Advanced ctDNA analysis yields biomarkers of cancer dynamics essential in therapeutic monitoring & intervention. Learn how NeXT Personal® detects MRD, monitors variants, & delivers powerful insights. |
|
Thursday, January 19, 2023 | 11:00am ET In this webinar, hear how Novartis uses social data from public forums worldwide to understand the educational and emotional needs of patients with Myelodysplastic Syndromes (MDS), and thereby create more targeted solutions to meet these needs. Register now.
|
|
By Eric Sagonowsky As Teva’s new CEO Richard Francis settles into his role, he’s already sharing thoughts on strategic priorities just days into the job. |
By James Waldron GSK is continuing to grow its footprint in the biotech hub of Boston, adding 155,000 square feet of additional lab space to its site on Cambridge Park Drive as part of its RNA focus. |
By Max Bayer Some nine months after Nektar's bempeg implosion, the company is pinning comeback hopes on two clinical-stage assets, one of which is part of a collaboration with Lilly. That asset, rezpeg, is slated for a critical phase 2 readout in lupus around mid-year. |
By Max Bayer Ionis once had AstraZeneca involved with and spied a bright future for PCSK9 inhibitor ION449. Now, after the U.K. pharma backed out last year, CEO Brett Monia, Ph.D., thinks the drug may have missed its shot. |
By Andrea Park As biotech and pharma have grown in prominence at the annual J.P. Morgan Healthcare Conference, it begs the question of where medtech makers fit in at the meeting—if at all. |
By Joseph Keenan Pinnacle Clinical Research, part of the LongueVue Capital portfolio, completed its acquisition of the South Texas Research Institute, which is known for its clinical research of nonalcoholic steatohepatitis. |
By Robert King HHS Secretary Xavier Becerra has extended the COVID-19 public health emergency again for another 90 days and possibly for the last time. |
By Joseph Keenan IMA Group, parent of IMA Clinical Research, acquired Clinical Trials of America for an undisclosed sum, extending the company’s presence in the U.S. southeast. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong,James Waldron Join us for a rolling look at the top life sciences news coming out of this year's virtual J.P. Morgan Healthcare Conference. |
Fierce podcastsDon't miss an episode |
| | This week on “The Top Line,” we discuss the biotech industry’s rotten tomatoes. Plus, we cover the drug approvals of last year, a congressional report on Biogen's "inappropriate" communications with the FDA and other top headlines from this week. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 1:00pm ET This session will discuss key 2023 trends for healthcare and life sciences and how organizations should think about their data strategy and interoperability as they navigate the winds of change. Register now.
|
|
| WhitepaperThis paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
